歌礼制药(01672.HK)旗下药品治疗新型肺炎临床研究之所有患者已出院
歌礼制药(01672.HK)公布,有关由南昌市第九医院陈宏义主任团队发起的口服戈诺卫(达诺瑞韦)联合利托那韦治疗新型冠状病毒肺炎小样本临床研究(NCT04291729),于今年2月16日获南昌市第九医院伦理委员会批准一事。该研究的治疗组之一,口服戈诺卫联合利托那韦治疗组,计划入组10例新型冠状病毒肺炎患者,实际入组11例患者。
集团指,目前所有11例接受口服戈诺卫联合利托那韦治疗的患者均已达到国家卫生健康委员会发布的《新型冠状病毒肺炎诊疗方案(试行第六版)》的出院标准後出院。
戈诺卫(达诺瑞韦)是口服丙肝病毒蛋白(酉每)抑制剂,於2018年6月获得国家药品监督管理局批准上市,用於治疗慢性丙型肝炎,为公司已商业化的产品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.